AAVantgarde Bio

AAVantgarde Bio has two proprietary, AAV-based large gene delivery platforms. The first leveraging DNA recombination, named dual hybrid; and the second, a protein trans-splicing, named AAV intein.

AAVantgarde is a clinical stage, Italian headquartered, international biotechnology company.

It is validating its two proprietary AAV platforms in the clinic in two inherited retinal diseases with the potential that its technology could extend into many disease areas. AAV gene therapy has been limited by transgene capacity, and the Company’s platforms enable delivery of large genes to tissue and cells in vivo.